GILD

NASDAQ · Biotechnology

Gilead Sciences Inc

S&P 500 Nasdaq 100 Large-Cap Stocks Blue Chip Stocks Biotech Stocks Healthcare Stocks Best Dividend Stocks

$139.37

+3.03 (+2.22%)

Financial Highlights (FY 2026)

Revenue

29.12B

Net Income

8.42B

Gross Margin

78.8%

Profit Margin

28.9%

Rev Growth

+2.6%

D/E Ratio

1.10

Revenue & Net Income

Margin Trends

	FY 2026	FY 2025	FY 2024	FY 2023
Gross Margin	78.8%	78.8%	53.5%	53.5%
Operating Margin	34.0%	30.6%	-33.3%	-35.4%
Profit Margin	28.9%	27.5%	-32.6%	-32.2%

Income Statement

	FY 2026	FY 2025	FY 2024	FY 2023
Revenue	29.12B	28.39B	56.82B	62.77B
Gross Profit	22.96B	22.39B	30.40B	33.58B
Operating Income	9.91B	8.70B	-18,927,955,656	-22,233,853,953
Net Income	8.42B	7.39B	-18,545,178,243	-20,228,320,493
Gross Margin	78.8%	78.8%	53.5%	53.5%
Operating Margin	34.0%	30.6%	-33.3%	-35.4%
Profit Margin	28.9%	27.5%	-32.6%	-32.2%
Rev Growth	+2.6%	+2.6%	-2.6%	+18.5%

Balance Sheet

	FY 2026	FY 2025	FY 2024	FY 2023
Total Debt	43.62B	43.62B	23.22B	22.16B
Total Equity	39.71B	39.71B	127.95B	131.01B
D/E Ratio	1.10	1.10	0.18	0.17

Cash Flow

	FY 2026	FY 2025	FY 2024	FY 2023
EBITDA	10.28B	9.52B	-26,008,242,356	-28,250,733,263
Free Cash Flow	—	—	-20,166,967,145	-15,276,791,822